|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Shire_plc
|
|
gptkbp:advertising
|
gptkb:Mr._Tetsuya_Saito
|
|
gptkbp:CEO
|
gptkb:Christophe_Weber
|
|
gptkbp:clinicalTrials
|
Ongoing
|
|
gptkbp:employees
|
50,000+
|
|
gptkbp:founded
|
1781
|
|
gptkbp:globalPresence
|
Over 70 countries
|
|
gptkbp:headCoach
|
gptkb:Dr._Andrew_Plump
gptkb:Ms._Rika_Tanaka
gptkb:Dr._Akiko_Saito
gptkb:Mr._Yoshio_Takeda
gptkb:Dr._Hiroshi_Watanabe
gptkb:Mr._Hiroshi_Saito
gptkb:Ms._Rika_Watanabe
gptkb:Mr._Taro_Yamada
gptkb:Dr._Hiroshi_Saito
gptkb:Dr._John_Smith
gptkb:Mr._Kazuhiro_Yamamoto
gptkb:Dr._Kenji_Watanabe
gptkb:Dr._Thomas_W._H._Hwang
gptkb:Ms._Akiko_Watanabe
gptkb:Mr._Shojiro_Tanaka
gptkb:Mr._Masahiro_Yamamoto
gptkb:Ms._Aiko_Nishida
gptkb:Ms._Yoko_Takahashi
gptkb:Mr._Kenjiro_Matsumoto
gptkb:Dr._Akira_Matsumoto
gptkb:Mr._Hiroshi_Nakagawa
gptkb:Mr._Kenji_Suzuki
gptkb:Mr._Yoshinori_Takeda
gptkb:Ms._Harumi_Sato
gptkb:Ms._Yuki_Sato
gptkb:Mr._Shoji_Takeda
Dr. Ryujiro Sato
Mr. Masato Tanaka
|
|
gptkbp:headOfMarketing
|
gptkb:Ms._Akiko_Tanaka
gptkb:Dr._Richard_D._Hargreaves
gptkb:Ms._Yoko_Saito
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda Pharmaceuticals International AG
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:insuranceAccepted
|
gptkb:Ms._Haruko_Yamamoto
|
|
gptkbp:partnerships
|
gptkb:Novavax
gptkb:Moderna
|
|
gptkbp:products
|
Vaccines
Oncology drugs
Rare disease treatments
|
|
gptkbp:researchAndDevelopment
|
gptkb:Mr._Tetsuya_Watanabe
|
|
gptkbp:researchFocus
|
Gastroenterology
Immunology
Neurology
Hematology
|
|
gptkbp:revenue
|
$30 billion (2022)
|
|
gptkbp:stockSymbol
|
4502 (TSE)
|
|
gptkbp:subsidiary
|
gptkb:Takeda_Pharmaceuticals_Europe_Ltd.
Takeda Pharmaceuticals USA, Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Diversity and inclusion
Environmental responsibility
Access to medicine
|
|
gptkbp:website
|
www.takeda.com
|